PDCD1 and neoplasm: ARMed EGFRvIII CAR T cells secreting PD1 minibody further augmented tumor control, with significantly increased overall survival compared to CAR T alone, median OS not reached at 50d, 80% of mice surviving to end of study in this subcutaneous GBM model.